Release issued 16th June 2004

June 16, 2004--Waltham, Mass.--Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience, especially in advanced stages of the disease. A related constraining factor is a lack of early diagnosis, most patients are diagnosed at an advanced disease stage, so the benefits of treatment are outweighed by their toxicities and inconvenience.

The new Pharmacor study entitled Pancreatic Cancer also finds that the launch of therapeutic vaccines such as Aphton/Aventis Pasteur's Gastrimmune and Lorus's Virulizin will be the major market driver.

"Gastrimmune will be the first therapeutic vaccine to launch and will initially be used to treat unresectable, advanced pancreatic cancer patients not fit enough to receive gemcitabine," said Mohamed Muhsin, M.Sc., analyst at Decision Resources. "This use of Gastrimmune will lead to a rise in the number of treated patients. Toward the end of the first half of our study period, Gastrimmune and Virulizin will be launched in combination with cytotoxic therapy; therefore, most patients, regardless of whether they receive gemcitabine, will be treated with a vaccine."

About Pancreatic Cancer: Pancreatic cancer is the fourth leading cause of cancer- related mortality. Surgical resection remains the only potentially curative option. However, resection alone is often insufficient: up to 85% of patients suffer recurrent disease, and more than 85% of patients are diagnosed at a stage of the disease that is too advanced for surgical intervention.

About Pharmacor from Decision Resources: Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources: Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

www.decisionresources.com

###

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread